Search PubMed⌕ Search

Biomedical subjects

R W Jones

Publications and source records attributed to R W Jones.

219 records · Page 13Linked to original sources

Signal intensity artifacts in clinical MR imaging.

Signal intensity artifacts are often encountered during magnetic resonance (MR) imaging. Occasionally, these artifacts are severe enough to degrade image quality and interfere with interpretation. Signal intensity artifacts inherent in local coil imaging include intensity gradients and local intensity shift artifact. The latter can be minimized but not eliminated with optimal coil design and tuning. Improper coil or patient positioning can produce subtle or, in some cases, severe signal intensity artifacts, and each is easily corrected. Signal intensity artifacts and image degradation can also occur in a perfectly functioning coil if protocols are not optimized. Failure of decoupling mechanisms can produce signal intensity artifacts that will not respond to protocol optimization and will worsen with gradient imaging. Improper coil tuning manifests as a shading artifact that can mimic other findings. Signal-degrading artifacts may be caused by a ferromagnetic foreign body in the imager. Signal intensity artifacts can also result from performing ultrafast imaging with coils that were not designed for this type of imaging or from MR imaging system malfunction. Familiarity with the various causes of signal intensity artifacts is necessary to maintain optimal image quality and should be required as part of any MR imaging quality assurance program.

Artifacts↗

Computer enhanced health risk reduction.

Computerized health profiles can effectively educate and motivate patients to develop habits that can reduce risk factors and contribute to a long, healthful life.

Health Status Indicators↗

Realistic expectations for treatment success in Alzheimer's disease.

Alzheimer's disease (AD) is a progressive degenerative disease that warrants active management to delay or slow progression of its symptoms. The symptoms of AD encompass behavior and daily function as well as cognition, so clinicians should take a global view in the assessment of treatment success. Because there is currently no cure for AD, one cannot expect an initial cognitive improvement observed in the first few months of therapy to be sustained indefinitely. However, one should expect that the patient who is treated early and persistently with medication for AD will show less evidence of behavioral, functional, and cognitive deterioration over a period of time than one would expect in the absence of pharmacotherapy. Thus, treatment success includes not only short-term improvement of symptoms but also less decline over the long term. Determination of treatment success therefore also requires awareness of the typical progression of untreated AD. In this article we review the natural history of AD and evidence for the effectiveness of the treatments indicated for AD: donepezil, galantamine, rivastigmine, and memantine.

Aged↗